Engene Therapeutics Inc (ENGN) SEC 13F Holdings (Q2 2026): Institutional Buyers & Sellers

ENGN ranks #5872 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

ENGN is a top-conviction position for BML Capital Management, LLC — at 6.6% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

ENGN is up 1.9% today, and institutions have been net buyers of $67.5M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ENGN reported a net loss of $117.3M in its latest fiscal year.

• Not yet profitable — net loss of $117.3M in the latest fiscal year
• Net income declined year over year, from -$55.1M to -$117.3M
• Operating cash flow was negative, using $99.2M in cash
• Current ratio of 6.30x — enough short-term assets to cover short-term liabilities
• Liabilities run 1.32x equity — within a conventional range